首页 > 市场调查报告书 > 製药

个人化医学

市场调查报告书

商品编码

1593450

个人化医疗市场规模、份额、成长分析、按产品、按应用、按最终用户、按地区 - 行业预测，2024-2031 年

Personalized Medicines Market Size, Share, Growth Analysis, By Product, By Application, By End Users, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月09日 | 出版商:

SkyQuest | 英文 209 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球个人化医疗市场规模将为5,120亿美元，从2023年的5,703.7亿美元成长到2031年的1,3528.1亿美元，并且预计在预测期内（2024-2031年）将以复合年增长率成长。 2019 年为11.40%。

全球个人化医疗市场是由基因技术整合所驱动的，旨在为个别患者提供量身定制的治疗。由于每个人类基因组都是独特的，个人化医疗旨在提供特定的诊断和治疗，特别是针对癌症。虽然肿瘤学仍然是主要关注点，但遗传技术的日益普及也刺激了对非肿瘤学应用的需求。基因技术正在经历两位数的成长，投资的增加正在推动进步。这为个人化医疗治疗阿兹海默症和帕金森氏症等罕见疾病创造了新的可能性。儘管医疗保健领域的采用历来进展缓慢，但医疗保健预算的增加以及製药公司与政府机构之间合作的加强预计将在未来几年加速个性化医疗的采用。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Roche Holding AG（Switzerland）
Bristol-Myers Squibb Company（USA）
AstraZeneca PLC（United Kingdom）
Gilead Sciences, Inc.（USA）
Amgen Inc.（USA）
Siemens Healthineers（Germany）
Guardant Health, Inc.（USA）
Exact Sciences Corporation（USA）
EMD Serono, Inc.（USA）
Bio-Rad Laboratories, Inc.（USA）
QIAGEN NV（Netherlands）
Myriad Genetics, Inc.（USA）
AbbVie Inc.（USA）
Takeda Pharmaceutical Company（Japan）
Caris Life Sciences, Inc.（US）
MDxHealth SA（Belgium）
Personalis, Inc.（US）
Freenome Holdings, Inc.（US）
Haplogen, Inc.（US）
Molecular Partners AG（Switzerland）
SOPHiA GENETICS SA（Switzerland）
NantHealth, Inc.（US）
Zymeworks Inc.（Canada）
Celerion（US）

简介目录

Product Code: SQMIG35H2307

Global Personalized Medicine Market size was valued at USD 512 billion in 2022 and is poised to grow from USD 570.37 billion in 2023 to USD 1352.81 billion by 2031, growing at a CAGR of 11.40% during the forecast period (2024-2031).

The global Personalized Medicines Market is driven by the integration of genetic technology to deliver tailored treatments for individual patients. As each human genome is unique, personalized medicine aims to provide specific diagnoses and treatments, particularly for cancer. While oncology remains a major focus, the rising availability of genetic technology is spurring demand for non-oncology applications as well. Genetic technology is experiencing double-digit growth, with increasing investment propelling advancements. This has opened new possibilities for personalized medicine in treating rare diseases, including Alzheimer's and Parkinson's. Despite the historically slow adoption in healthcare, growing healthcare budgets and increased collaborations between pharmaceutical companies and government agencies are expected to accelerate the adoption of personalized medicine in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Personalized Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Personalized Medicine Market Segmental Analysis

Global Personalized Medicine Market is segmented by Product, Application, End Users, and region. Based on Product, the market is segmented into Personalized Medicine Testing (Genetic Testing, DTC Testing, Others), Personalized Medicine Therapeutics (Pharmaceuticals, Medical Devices, Others), Personalized Medical Care (Telemedicine, Health Information Technology), Personalized Nutrition & Wellness (Retail Nutrition, Complementary & Alternative Medicine). Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Antiviral, Psychiatry, Immunology, and Others. Based on End Users, the market is segmented into Hospitals And Clinical Care, Diagnostic Companies and Testing Facilities, Academic Research Institutes and Research Laboratories, Contract Research Organizations, Bio and Health Informatics Companies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Personalized Medicine Market

The rapid advancement of genetic technology is significantly influencing the healthcare and pharmaceutical industries, driving the demand for personalized medicines. With the genetic technology market valued at over USD 5 billion and anticipated to grow at a compound annual growth rate (CAGR) of more than 20% throughout the forecast period, the sector is attracting increasing investments. This growth is expected to enhance the availability, accessibility, and demand for personalized medicines, paving the way for more tailored and effective treatments. As genetic innovations continue to evolve, the integration of these technologies into personalized medicine is set to revolutionize healthcare delivery, further accelerating market expansion.

Restraints in the Global Personalized Medicine Market

One of the key restraints for the global Personalized Medicines Market is the slow adoption of new technologies within the healthcare industry. The sector is typically conservative in integrating advanced innovations like AI and genetic engineering, largely due to stringent regulations. Regulatory bodies impose strict guidelines on the use of these technologies in healthcare applications, and authorities are often hesitant to approve their widespread adoption until they are fully confident in their safety and effectiveness. This cautious approach significantly delays the implementation of cutting-edge technologies in personalized medicine, hindering market growth and innovation in the field.

Market Trends of the Global Personalized Medicine Market

A significant trend in the global Personalized Medicines Market is the increase in healthcare budgets across both developed and developing economies, a shift that has gained momentum in the post-pandemic era. While stagnant healthcare budgets had been a concern for many years, governments have notably boosted funding for healthcare, which is directly fueling research and development (R&D) in alternative treatments and personalized medicines. This rise in healthcare expenditure is improving access to personalized medicine for patients who require tailored treatments and can afford them, thereby driving market growth and expanding patient access to innovative therapeutic options.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Value Chain Analysis
Patent Analysis
Case Study Analysis
Technology Analysis

Personalized Medicines Market by Product

Market Overview
Personalized Medicine Testing
- Genetic Testing
- DTC Testing
- Others
Personalized Medicine Therapeutics
- Pharmaceuticals
- Medical Devices
- Others
Personalized Medical Care
- Telemedicine
- Health Information Technology
Personalized Nutrition & Wellness
- Retail Nutrition
- Complementary & Alternative Medicine

Personalized Medicines Market by Application

Market Overview
Oncology
Neurology
Cardiology
Antiviral
Psychiatry
Immunology
Others

Personalized Medicines Market by End Users

Market Overview
Hospitals And Clinical Care
Diagnostic Companies and Testing Facilities
Academic Research Institutes and Research Laboratories
Contract Research Organizations
Bio And Health Informatics Companies
Others

Personalized Medicines Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EMD Serono, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MDxHealth SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personalis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Freenome Holdings, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haplogen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Molecular Partners AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SOPHiA GENETICS SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantHealth, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celerion (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments